Nelipepimut S - Galena Biopharma

Drug Profile

Nelipepimut S - Galena Biopharma

Alternative Names: Cancer vaccine E75; Cancer vaccine E75 - Apthera; Cancer vaccine Her2/neu E75 - Apthera; E75; E75 peptide; E75/GM-CSF vaccine; Nelipepimut-S; NeuVax

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Breast cancer
  • Phase I Gastric cancer
  • Preclinical Pancreatic cancer
  • No development reported Bladder cancer; Ovarian cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Intradermal)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Intradermal)
  • 28 Sep 2017 Galena Biopharma completes enrolment in two phase II trial for Breast cancer in USA (NCT02297698) (NCT01570036)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top